Aurobindo Pharma Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

The product is bioequivalent and therapeutically equivalent to the reference listed drug, Xeljanz Tablets, of PF Prism C.V. It will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of the company, and is scheduled for immediate launch.

According to IQVIA MAT data for the 12 months ended April 2026, the US market for Tofacitinib tablets is estimated at approximately $494 million. Following this approval, Aurobindo Pharma has a total of 586 ANDA approvals from the USFDA, comprising 561 final approvals and 25 tentative approvals.

Tofacitinib tablets are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and moderately to severely active ulcerative colitis, specifically in cases where patients have had an inadequate response or intolerance to prior standard therapies such as methotrexate or other disease-modifying antirheumatic drugs. In ulcerative colitis, the use also applies to patients who have not responded adequately or are intolerant to TNF (tumour necrosis factor) blockers.

Separately, the company inaugurated TheraNym, its dedicated biologics contract manufacturing organization (CMO), marking its entry into the biologics contract manufacturing segment. Located at Borapatla near Hyderabad, the facility is positioned as one of India's largest dedicated biologics CMOs.

Aurobindo Pharma said MSD (known as Merck & Co. in the US and Canada) will serve as the anchor customer for the facility, which has been established to support domestic and export supply requirements, subject to applicable approvals and customer requirements.

Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 2% rise in consolidated net profit to Rs 921.26 crore on a 4.4% increase in net sales to Rs 8,751.50 crore in Q4 FY26 over Q4 FY25.

Powered by Capital Market - Live News

Aurobindo Pharma has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Tofacitinib Tablets, 5 mg and 10 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xeljanz Tablets, 5 mg and 10 mg, of PF Prism C.V.

The product will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of the company and will be launched immediately.

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-I, a formulation manufacturing facility, of Eugia Pharma Specialities, a wholly owned subsidiary of the Company, situated at Kolthur Village, Shameerpet Mandal, Ranga Reddy, 500078, Telangana, from February 16 to February 27, 2026. The inspection had concluded with 4 observations.

FDA has now determined that the inspection classification of this facility is ?official action indicated? (OAI).

Net profit of Aurobindo Pharma rose 1.97% to Rs 921.26 crore in the quarter ended March 2026 as against Rs 903.47 crore during the previous quarter ended March 2025. Sales rose 4.42% to Rs 8751.50 crore in the quarter ended March 2026 as against Rs 8381.12 crore during the previous quarter ended March 2025.

For the full year,net profit rose 0.54% to Rs 3504.75 crore in the year ended March 2026 as against Rs 3485.88 crore during the previous year ended March 2025. Sales rose 6.39% to Rs 33384.74 crore in the year ended March 2026 as against Rs 31378.13 crore during the previous year ended March 2025.

Powered by Capital Market - Live News